Last week, Sonnet BioTherapeutics ($SONN) has closed the deal of a reverse merger with Chanticleer Holdings and has gone on to announce a Scientific Advisory Board.
Sonnet is privileged to have this distinguished group of scientific advisors from leading institutions to help guide our clinical development and discovery programs, The advisors come to the company after reviewing its assets and are excited to be a part of the team. They share deep experience in oncology drug development from initial discovery to late-stage clinical studies, which will enhance our strategic efforts through the next phase of growth.
Pankaj Mohan, Ph.D, Sonnet BioTherapeutics CEO
The board members include:
Jason Bock, Ph.D., – Dr. Bock is the Vice President and Head of Biologics Product Development at MD Anderson Cancer Center. In this role, Dr. Bock works with MD Anderson’s Therapeutic Discovery team, including world-class oncology researchers and clinicians, to create life-saving transformational medicines quickly, safely and effectively. Before joining MD Anderson, Dr. Bock spent 20 years in small, medium and large biotech and biopharma companies (including Human Genome Sciences, CoGenesys and TEVA) developing biologic therapeutics. He has brought 15 novel drugs through preclinical development into clinical studies and has guided the process to bring three biologics through the clinic and to commercialization globally. He received his Ph.D. from Stanford University in Molecular & Cellular Physiology.
Joseph R. Bertino, M.D., – Dr. Bertino is University Professor of medicine and pharmacology, UMDNJ-Robert Wood Johnson Medical School and is the interim director of the school’s Cancer Institute of New Jersey. Dr. Bertino joined The Cancer Institute of New Jersey in 2002 as associate director and was appointed chief scientific officer in 2004. Previously, Dr. Bertino served as chair of the Molecular Pharmacology and Therapeutics Program, and member and co-head of the Program in Developmental Therapy and Clinical Investigation at Memorial Sloan-Kettering Institute for Cancer Research. Dr. Bertino has been internationally recognized for his role in finding curative treatments for leukemia and lymphoma. He is the author or co-author of more than 400 scientific publications and the associate medical editor of the journal Hem/Onc Today. After earning his medical degree, Dr. Bertino did a USPHS fellowship in hematology and oncology at the University of Washington School of Medicine.
Hossein Borghaei, D.O., M.S., – Dr. Borghaei is Chief of Thoracic Medical Oncology at Fox Chase Cancer Center, where he is also a Professor in the Department of Oncology/Hematology, Co-Director of the Immune Monitoring Facility and the Gloria and Edmund M. Dunn Chair in Thoracic Malignancies. In his clinical practice, Dr. Borghaei has participated in numerous immunotherapy-based clinical trials. He is also the principal investigator (PI) of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs. He served as the PI of a phase III randomized study that proved the effectiveness of nivolumab in the treatment of patients with advanced non-squamous non-small cell lung cancer after progression on prior chemotherapy. This work led to the approval of nivolumab, one of the first immunotherapy-based drugs to be approved for lung cancer in this setting. Dr. Borghaei earned his D.O. degree at Philadelphia College of Osteopathic Medicine, did his residency at Graduate Hospital (Philadelphia) and was Chief Fellow, Hematology-Oncology, at Fox Chase Cancer Center.
Guido Cavaletti, M.D., – Dr. Cavaletti is Dean of Research and Professor at the University of Milan-Bicocco, and Senior consultant neurologist and head of the Neuroimmunology Center, S. Gerardo Hospital, Monza (Italy). At the University of Milan-Bicocco, he is Head of the Experimental Neurology Unit at the School of Medicine and Surgery and Director of the Ph.D. program in Neuroscience. He is also Deputy Scientific Director of the Milan Center for Neuroscience (NeuroMI). Dr. Cavaletti is coordinator of the steering committee of the international CI-PeriNoms group on the investigation of chemotherapy-induced peripheral neurotoxicity. He has authored more than 250 peer-reviewed papers. He received his medical degree from the University of Milan and is Board-certified in Neurology.
Should you Invest in Sonnet BioTherapeutics ($SONN)?
I would highly recommend digging into this company, their pipeline is strong and the drugs they use may be already approved by the FDA in different circumstances and uses.
Sonnet BioTherapeutics ($SONN) Financials
Sonnet BioTherapeutics ($SONN) skyrocketed to the green zone last week, turning into a positive trend and surging by +1,650%. With this latest performance, SONN shares surged by +10% in over the last four-week period, additionally plunging -54% over the last 6 months.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SONN stock in for the last two-week period is set at 45.51, with the RSI for the last single day of trading hit 24.32, and the three-weeks RSI is set at 49.91 for Sonnet BioTherapeutics ($SONN). The present Moving Average for the last 50 days of trading for this stock 4, while it was recorded at 5 for the last single week of trading, and 3 for the last 200 days.
Insight into Sonnet BioTherapeutics
Operating Margin for any stock indicates how profitable investing would be, and Sonnet BioTherapeutics ($SONN) shares currently have an operating margin of 1%. Sonnet BioTherapeutics’s Net Margin is presently recorded at 1%.
Return on Total Capital for SONN is now 1%, given the latest momentum, and Return on Invested Capital for the company is 1. Return on Equity for this stock increased to 0, with Return on Assets sitting at 1. When it comes to the capital structure of this company has a Total Debt to Total Equity ratio set at 1. Additionally, SONN Total Debt to Total Capital is recorded at 1, with Total Debt to Total Assets ending up at. Long-Term Debt to Equity for the company is recorded at 1, with the Long-Term Debt to Total Capital now at 1.
Reflecting on the efficiency of the workforce at the company, Sonnet BioTherapeutics ($SONN) managed to generate an average of millions in revenue. Receivables Turnover for the company is 0 with a Total Asset Turnover recorded at a value of 0. SONN’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0 and a Current Ratio set at 0.
Sonnet BioTherapeutics Insider Details
